Generic Name and Formulations:
Ioxilan 300mgI/mL, 350mgI/mL; soln for IV inj; preservative-free.
Indications for OXILAN:
Intraarterial: For cerebral arteriography (300mgI/mL). For coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography (350mgI/mL). IV: For excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300mgI/mL and 350mgI/mL).
Individualize. Intraarterial procedures: Left and right coronary: 2–10mL. Left ventricle: 25–50mL. Aortography and selective visceral: see literature. Aortic bifurcation for distal runoff: 45–100mL. Subclavian or femoral artery: 10–40mL. Total dose for procedure should not exceed 250mL. Cerebral arteriography: 8–12mL; total dose for procedure should not exceed 150mL. IV procedures: Excretory urography: 250–390mgI/kg; total dose for procedure should not exceed 100mL. CECT of the head: 100–200mL (300mgI/mL) or 86–172mL (350mgI/mL); total dose for procedure should not exceed 200mL. CECT of body: 50–200mL (300mgI/mL) or 43–172mL (350mgI/mL); total dose for procedure should not exceed 200mL.
Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Homocystinuria: avoid. Severe renal impairment. Combined renal and hepatic disease. Combined renal and cardiac disease. CHF. Diabetes. Severe thyrotoxicosis. Myelomatosis. Anuria. Pheochromocytoma. Homozygous sickle cell disease. Immune disorders. Maintain adequate hydration. History of sever cutaneous hypersensitivity reaction; avoid. Avoid extravasation. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Nonionic contrast agent.
Headache, fever, hematoma at inj site, chills, angina, hypertension, bradycardia, hypotension, GI upset, dizziness, urticaria, rash; thromboembolic events, hypersensitivity reactions, severe cutaneous reactions (eg, SJS/TEN, AGEP, DRESS).
Single-dose bottles (50mL, 100mL, 150mL, 200mL)—10
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders